AAS
ANEB

Ameritas Advisory Services’s Anebulo Pharmaceuticals ANEB Stock Holding History

Ameritas Advisory Services’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$14 – 2135
2025
Q2 		$14 Buy
+10
New +$11 ﹤0.01% 2823

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameritas Advisory Services's ANEB Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Anebulo Pharmaceuticals (ANEB) in Q3 2025, closing a stake of 10 shares — an estimated $14 sold.

Ameritas Advisory Services first reported a position in ANEB in Q2 2025 and held it in 1 quarter. The position peaked at $14 in Q2 2025. 21 funds tracked by Wall St. Rank hold ANEB as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Anebulo Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 10 Anebulo Pharmaceuticals shares in Q3 2025, an estimated $14.
  • Ameritas Advisory Services first reported a position in Anebulo Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Ameritas Advisory Services's Anebulo Pharmaceuticals position peaked at $14 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.